We evaluated electrical velocimetry, a noninvasive method for continuous cardiac output measurement, in very-low and low birth weight infants and the influence of patent ductus arteriosus (PDA) and ...

Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...

Pediatric experts from Le Bonheur’s Heart Institute and the University of Tennessee Health Science Center will present lectures, posters, abstracts and hands-on workshops. Pediatric experts from Le ...

Patent ductus arteriosus (PDA) is a congenital cardiac defect that occurs when the ductus arteriosus fails to close. The result is a persistent communication between the aorta and pulmonary artery, ...

Patent ductus arteriosus (PDA), one of the more common cardiac defects present at birth, is the persistence of an opening between the pulmonary artery and aorta. This opening is as a result of failure ...

The U.S. IDE clinical trial will evaluate the safety and effectiveness of the St. Jude Medical™ AMPLATZER™ Duct Occluder II AS (ADO II AS), a first-of-its-kind device specifically designed for closure ...

As babies make the transition of depending on the mother for oxygen and depending on their own lungs during birth, an arterial connection has to close on its own. Normally this transition occurs ...